Alder Therapeutics develops allogeneic stem cell therapies, specifically ALD01 for Retinitis Pigmentosa and ALD02 for heart failure, both supported by preclinical data demonstrating efficacy in relevant animal models. These therapies aim to provide treatment options for conditions currently lacking effective solutions, such as mutation-agnostic approaches for inherited blindness and restoration of heart function in heart failure patients.
Funding
$3.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for Retinitis Pigmentosa (RP) are limited, with only one single-mutation gene therapy available to a small subset of patients, leaving the majority without effective options. Existing treatments for heart failure are often invasive, expensive, and primarily address symptoms rather than restoring heart function.
Solution
Alder Therapeutics is developing allogeneic stem cell therapies, ALD01 for Retinitis Pigmentosa and ALD02 for heart failure, designed to address the limitations of current treatment paradigms. ALD01 is a retinal cell therapy that offers a mutation-agnostic approach for treating RP, potentially benefiting a broader range of patients than existing gene therapies. ALD02, a cardiac cell therapy, aims to restore heart function, offering a more comprehensive solution compared to treatments focused solely on managing heart failure symptoms. Both therapies are supported by preclinical data demonstrating efficacy in relevant large animal models, suggesting their potential to translate into effective clinical treatments. The company employs a unique drug development philosophy, the AlderEdge, focused on de-risking cell therapy development by keeping the commercial product in mind from the start.
Target Audience
The primary target audience includes patients with Retinitis Pigmentosa and heart failure, as well as clinicians and healthcare providers seeking advanced therapeutic options for these conditions.
Features
- ALD01: Allogeneic stem cell-derived retinal cell therapy for Retinitis Pigmentosa, designed to be mutation-agnostic.
- ALD02: Allogeneic stem cell-derived cardiac cell therapy for heart failure, aimed at restoring heart function.
- Preclinical proof-of-concept data in relevant large animal models for both ALD01 and ALD02.
- AlderEdge approach: A drug development philosophy focused on de-risking cell therapy development.
- Focus on developing therapies for conditions with limited or no effective treatment options.